Cyclical intravenous pamidronate therapy increases bone mass in children with
osteogenesis imperfecta (OI), but the effect on the intrinsic material properties of bone is …

Cyclical intravenous treatment with pamidronate is of clinical benefit in children with
moderate to severe osteogenesis imperfecta (OI) types I, III and IV, but there is no …

Clinical and histomorphometric outcome was compared between children with OI who had
received pamidronate since infancy and age‐matched patients who had never received …

Osteogenesis imperfecta (OI) is a term used to describe a group of inherited connective
tissue conditions that are characterized by increased bone fragility and low bone mass. With …

Cyclical intravenous therapy with pamidronate improves the clinical course in children and
adolescents with osteogenesis imperfecta (OI). In this study, we evaluated the effect of this …

Osteogenesis imperfecta is a skeletal dysplasia characterized by bone fragility and
extraskeletal manifestations. Better understanding of the mechanisms of osteogenesis …

Osteogenesis imperfecta is a genetic disorder of type I collagen. Although multiple
genotypes and phenotypes are associated with osteogenesis imperfecta, approximately …

Osteogenesis imperfecta type I (OI-I) represents the mildest form of OI. The collagen I
mutations underlying the disorder can be classified as quantitative mutations that lead to …

Osteogenesis imperfecta, discussed in Baldridge et al. 2008 is an inherited bone fragility
disorder with a wide range of clinical severity that in the majority of cases is caused by …

Background Non-randomised studies have suggested beneficial effects of bisphosphonates
in osteogenesis imperfecta. We assessed the effects of oral olpadronate in children with this …